BioCentury | Oct 31, 2019
Company News

Dicerna’s latest deal lands $200M, Roche as partner in HBV

...trial of its next-generation RNAi therapy, AB-729, in June. Arbutus discontinued a more advanced therapy, ARB-1467...
BioCentury | Oct 12, 2018
Company News

Arbutus falls on HBV program updates

...way forward." Additionally, the company reported interim data from a Phase II trial of its ARB-1467...
...six by the prespecified threshold required to move to the peginterferon treatment stage of trial. ARB-1467...
...of Johnson & Johnson (NYSE:JNJ). Arbutus Biopharma Corp. (NASDAQ:ABUS), Burnaby, B.C. Business: Infectious Elizabeth S. Eaton AB-452 ARB-1467, tkm-hbv Arbutus...
BioCentury | Oct 9, 2018
Clinical News

Arbutus falls on HBV program updates

...way forward." Additionally, the company reported interim data from a Phase II trial of its ARB-1467...
...six by the prespecified threshold required to move to the peginterferon treatment stage of trial. ARB-1467...
...team leader at the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ). Elizabeth S. Eaton AB-452 ARB-1467, tkm-hbv Arbutus...
BioCentury | Sep 14, 2018
Clinical News

Arrowhead's third-generation RNAi shows initial efficacy against HBV

...HBV (see "Mining the Negatives" ). Fellow RNAi company Arbutus Biopharma Corp. (NASDAQ:ABUS) is developing ARB-1467...
...regions of the HBV viral genome. In the Phase IIa ARB-1467-002 trial, 0.4 mg/kg IV ARB-1467...
BioCentury | Sep 6, 2018
Clinical News

Arrowhead's third-generation RNAi shows initial efficacy against HBV

...HBV (see "Mining the Negatives" ). Fellow RNAi company Arbutus Biopharma Corp. (NASDAQ:ABUS) is developing ARB-1467...
...regions of the HBV viral genome. In the Phase IIa ARB-1467-002 study, 0.4 mg/kg IV ARB-1467...
BioCentury | Dec 1, 2017
Clinical News

Arbutus' ARB-1467 leads to HBsAg responses in Phase IIa for HBV infection

...infection in cohort 4 of the Phase IIa ARB-1467-002 trial showing that 0.4 mg/kg IV ARB-1467...
...ARB-1467 every other week, respectively. Cohort 3 enrolled HBeAg-positive patients to receive 0.4 mg/kg once-monthly ARB-1467...
...2H18 and final data in 2019. Arbutus Biopharma Corp. (NASDAQ:ABUS), Burnaby, B.C. Product: ARB-1467 (formerly TKM-HBV...
BioCentury | Oct 12, 2017
Targets & Mechanisms

Mining the negatives

...said. Arcturus has also licensed its UNA chemistry to Arbutus Biopharma Corp. , which has ARB-1467...
...the HBV viral genome, in Phase II testing for HBV. Esau noted clinical data for ARB-1467...
...II topline data for a cohort of 12 HBeAg-negative patients who received biweekly dosing of ARB-1467...
BioCentury | Aug 12, 2017
Product Development

HBV test kitchen

...viral genome; destabilizer of HBsAg and other viral mRNAs Capsid inhibitor; cccDNA inhibitor Checkpoint inhibitor ARB-1467...
...cells can recognize infected hepatocytes,” he said. Early data have shown Arbutus’ most advanced candidate, ARB-1467...
...benchmark novel agents must hit before they are put into combinations (see “Moving to POC”). ARB-1467...
BioCentury | May 23, 2016
Analyst Picks & Changes

Analyst picks & changes

...6% $4.08 Kumar initiated coverage with a $3.25 target, saying competition to Arbutus' lead asset, ARB-1467...
...NASDAQ:ALNY) and Benitec Biopharma Ltd. (ASX:BLT; NASDAQ:BNTC) "appear to have superior preclinical efficacy relative to ARB-1467."...
BioCentury | Oct 12, 2015
Clinical News

Arbutus Biopharma preclinical data

...In a mouse model of HBV infection, 4 weekly doses of 0.3 mg/kg TKM-HBV reduced HBV...
...vs. untreated control animals. This quarter, Arbutus expects data from a Phase I trial of TKM-HBV...
...highly conserved regions of the HBV viral genome. Arbutus Biopharma Corp. (NASDAQ:ABUS), Burnaby, B.C. Product: TKM-HBV...
Items per page:
1 - 10 of 16